Date: Friday 18 May 2012
A round-up of the biggest director deals today so far.
| Small caps round-up: Ark Therapeutics, Volex, Go... | 02-May-2012 | ShareCast |
| Small caps round-up: Plastics Capital, Vislink, ... | 25-Apr-2012 | ShareCast |
| Monday broker round-up | 12-Mar-2012 | ShareCast |
| Small caps round-up: Ambrian Capital, North Rive... | 08-Feb-2012 | ShareCast |
| Ark Therapeutics partnership achieves first mile... | 04-Jan-2012 | ShareCast |
| Holding(s) in Company | 18-May-2012 | 12:02 | RNS |
| Director Dealings | 18-May-2012 | 12:01 | RNS |
| Result of AGM | 18-May-2012 | 11:57 | RNS |
| Interim Management Statement | 17-May-2012 | 07:00 | RNS |
| Completion of Phase 1 Study | 16-May-2012 | 07:00 | RNS |
| Ark gains on hopes for cancer drug | 31-Jul-2008 | The Independent |
| Need to know | 31-May-2008 | Times |
| Ark perks up after regulators say brain tumour g... | 06-Jan-2007 | Telegraph |
| Database | 14-Oct-2006 | Telegraph |
| Ark breaks new ground in tackling cancer care si... | 20-Feb-2006 | Times |
| Investment Column:Ark Therapeutics | 12-Mar-2009 | The Independent |
| The Week Ahead: Kazakh and Tate & Lyle head for ... | 10-Mar-2008 | The Independent |
| Questor: Ark Therapeutics | 10-Nov-2007 | Telegraph |
| Analysts want Absolut news on Diageo's plans | 28-Aug-2007 | The Independent |
| Market report: Thursday latest | 08-Mar-2007 | Daily Mail |
No recent information was found.
| Yesterday's trading: Chaucer sparks buying frenzy | 17-Feb-2009 | This Is Money |
| Yesterday's trading: Biotech boosted by cancer d... | 31-Jul-2008 | This Is Money |
| Newspaper and magazine share tips | 24-Jun-2008 | This Is Money |
| Market report: Friday close | 16-May-2008 | This Is Money |
| Yesterday's trading: Footsie shrugs off credit ... | 30-Aug-2007 | This Is Money |
| Currency | UK Pounds |
| Share Price | 2.82p |
| Change Today | 0.040p |
| % Change | 1.44 % |
| 52 Week High | 5.35 |
| 52 Week Low | 2.70 |
| Volume | 737,270 |
| Shares Issued | 209.28m |
| Market Cap | £5.89m |
| Beta | 0.41 |
| RiskGrade | 371 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 2 |

| No dividends found |
| Time | Volume / Share Price |
| 15:11 | 21,549 @ 2.74p |
| 15:07 | 18,927 @ 2.75p |
| 12:43 | 300,000 @ 2.93p |
| 12:43 | 300,000 @ 2.90p |
| 11:10 | 2,650 @ 2.71p |
| CEO | Martyn Williams |
| CFO | Russell Banks |
You are here: research